It appears that Janssen Pharmaceuticals and other defendants behind the manufacture and marketing of the antipsychotic drug Risperdal (risperidone) owe the state of South Carolina $124 million. The U.S. Supreme Court on Jan. 11 refused to review Janssen's appeal of a $124 million civil penalty that the state imposed for not disclosing the drug's risks, notably the risk of the enlargement of male breasts, a condition known as gynecomastia.
Risperdal company owes South Carolina $124 million
It appears that Janssen Pharmaceuticals and other defendants behind the manufacture and marketing of the antipsychotic drug Risperdal (risperidone) owe the state of South Carolina $124 million. The U.S. Supreme Court on Jan. 11 refused to review Janssen's appeal of a $124 million civil penalty that the state imposed for not disclosing the drug's risks, notably the risk of the enlargement of male breasts, a condition known as gynecomastia.
Federal court's drug marketing ruling a Risperdal reminder
An Aug. 7 ruling by a federal district court in New York raised the issue of whether a drug company is culpable of "misbranding" a drug, in violation of federal regulations, when the company markets the drug for a purpose unapproved by the U.S. Food and Drug Administration. The case did not address in any way U.S. Justice Department and FDA proceedings in regard to the antipsychotic Risperdal, but it did address the broader issue of how far a drug company can go in the so-called "off-label" marketing of its product.
Federal court's drug marketing ruling a Risperdal reminder
An Aug. 7 ruling by a federal district court in New York raised the issue of whether a drug company is culpable of "misbranding" a drug, in violation of federal regulations, when the company markets the drug for a purpose unapproved by the U.S. Food and Drug Administration. The case did not address in any way U.S. Justice Department and FDA proceedings in regard to the antipsychotic Risperdal, but it did address the broader issue of how far a drug company can go in the so-called "off-label" marketing of its product.
Risperdal lawsuits from states move forward
Trial has been scheduled for April 2016 in the state of Kentucky's complaint against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc., in regard to the corporations' alleged misbranded promotion of the antipsychotic drug Risperdal (risperidone). J&J reported the trial timeline in its most recent quarterly report to the U.S. Securities and Exchange Commission.
Risperdal lawsuits from states move forward
Trial has been scheduled for April 2016 in the state of Kentucky's complaint against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals Inc., in regard to the corporations' alleged misbranded promotion of the antipsychotic drug Risperdal (risperidone). J&J reported the trial timeline in its most recent quarterly report to the U.S. Securities and Exchange Commission.
Risperdal settlement occurs amid growing litigation
Risperdal lawsuits continue to be filed in regard to the antipsychotic drug's side effects to male patients. Meanwhile, several defendants, including Janssen Pharmaceuticals, the manufacturer of Risperdal (risperidone), agreed May 18 to pay the State of Arkansas nearly $7.8 million to settle litigation in regard to the marketing of the drug. The agreement is contained in a May 18 order handed down by the state's Sixth Division Circuit Court of Pulaski County.
Risperdal settlement occurs amid growing litigation
Risperdal lawsuits continue to be filed in regard to the antipsychotic drug's side effects to male patients. Meanwhile, several defendants, including Janssen Pharmaceuticals, the manufacturer of Risperdal (risperidone), agreed May 18 to pay the State of Arkansas nearly $7.8 million to settle litigation in regard to the marketing of the drug. The agreement is contained in a May 18 order handed down by the state's Sixth Division Circuit Court of Pulaski County.
Risperdal victim awarded $2.5 million
Alabama native Austin Pledger started taking the antipsychotic Risperdal in 2002, when he was 8 years old, to treat autism symptoms. By the time he was a teenager, Pledger had been diagnosed with gynecomastia, the abnormal development of breasts in men. Reportedly, Pledger's breasts reached size 46DD. Instead of suffering in silence, the patient and his mother sought justice, as Risperdal clients of the law firm of Reich & Binstock also have done. And two months ago, a jury saw things Pledger's way.
Risperdal victim awarded $2.5 million
Alabama native Austin Pledger started taking the antipsychotic Risperdal in 2002, when he was 8 years old, to treat autism symptoms. By the time he was a teenager, Pledger had been diagnosed with gynecomastia, the abnormal development of breasts in men. Reportedly, Pledger's breasts reached size 46DD. Instead of suffering in silence, the patient and his mother sought justice, as Risperdal clients of the law firm of Reich & Binstock also have done. And two months ago, a jury saw things Pledger's way.
